Veterinary Medicines Information website

ProteqFlu (--) - Powder and solvent for suspension for injection

Not authorised
  • Canarypox virus, strain vCP1533, expressing haemagglutinin gene of Influenza A virus subtype H3N8 (A/equine/Newmarket/2/1993), Live
  • Canarypox virus, strain vCP1529, expressing haemagglutinin gene of Influenza A virus subtype H3N8 (A/equine/Kentucky/94), Live
Download as PDF

Product identification

Medicine name:
ProteqFlu (--) - Powder and solvent for suspension for injection
Active substance:
  • Canarypox virus, strain vCP1533, expressing haemagglutinin gene of Influenza A virus subtype H3N8 (A/equine/Newmarket/2/1993), Live
  • Canarypox virus, strain vCP1529, expressing haemagglutinin gene of Influenza A virus subtype H3N8 (A/equine/Kentucky/94), Live
Target species:
  • Horse
Route of administration:
  • Intramuscular use

Product details

Active substance and strength:
  • Canarypox virus, strain vCP1533, expressing haemagglutinin gene of Influenza A virus subtype H3N8 (A/equine/Newmarket/2/1993), Live
    Presentation_strength:6.5 log10 FAID*50 to 7.5 log10 FAID50 Reference:Hse Index:0
  • Canarypox virus, strain vCP1529, expressing haemagglutinin gene of Influenza A virus subtype H3N8 (A/equine/Kentucky/94), Live
    Presentation_strength:6.5 log10 FAID*50 to 7.5 log10 FAID50 Reference:Hse Index:1
Pharmaceutical form:
  • Powder and solvent for suspension for injection
Withdrawal period by route of administration:
  • Intramuscular use
    • Horse
      • Not applicable
        0
        day
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QI05AD02
Legal status of supply:
  • Medicinal product subject to medical prescription
Authorisation status:
  • Surrendered
Authorised in:
  • Austria
  • Belgium
  • Bulgaria
  • Croatia
  • Cyprus
  • Czechia
  • Denmark
  • Estonia
  • Finland
  • France
  • Germany
  • Greece
  • Hungary
  • Iceland
  • Ireland
  • Italy
  • Latvia
  • Liechtenstein
  • Lithuania
  • Luxembourg
  • Malta
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Romania
  • Slovakia
  • Slovenia
  • Spain
  • Sweden
  • United Kingdom (Northern Ireland)

Additional information

Entitlement type:
  • Marketing Authorisation
Legal basis of product authorisation:
  • Complete application (stand-alone) - Council Directive 81/851/EEC
Marketing authorisation holder:
  • Boehringer Ingelheim Vetmedica GmbH
Marketing authorisation date:
Manufacturing sites for batch release:
  • Boehringer Ingelheim Animal Health France
Responsible authority:
  • European Commission
Authorisation number:
This information is not available for this product.
Date of authorisation status change: